Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Mar. 13, 2025 — A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

The detection of metastases in Merkel cell carcinoma (MCC) requires additional testing, such as pancytokeratin (panCK) or CK20, with no guarantee of success. Recent findings have identified ...

Cancer can be a cause of low hemoglobin (anemia), and is often seen with cancer types that include leukemia, breast cancer, colon cancer, and prostate cancer. Chemotherapy and radiation treatments for ...

The gut microbiome has emerged as a potential factor in cancer pathogenesis, but its role in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) remains unclear. This study aimed to elucidate ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. The small-molecule drug is now allowed for patients 12 years of age and ...

In January 2025, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors were updated to include cabozantinib as a category 1 ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...